F rom 1995 to 1999, the prevalence of macrolide resistance among invasive pneumococci doubled to 20% in the United States (1) . The rise in the 1990s was primarily due to strains with an M phenotype, a surrogate marker for the mefE gene (1, 2) . In 1999, children <5 years of age and white persons had a higher proportion of M phenotype strains causing invasive disease than did older persons and black persons (1) . Most macrolide-resistant strains in the United States were also penicillin-nonsusceptible (1); modeling suggested that strains resistant to both drug classes would increase without a vaccine or other intervention (3) . Since the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, the overall incidence of macrolide-resistant infections, including serotype 14 strains, has decreased in Atlanta, Georgia (4) . It is unclear whether these changes are caused by shifts in a small number of clones. Most drug-resistant infections in the United States are related to a small number of international clones (5).
The Study
The Baltimore metropolitan area is one of the sites in the Active Bacterial Core system that conducts active, laboratory surveillance for invasive pneumococcal disease.
Approximately 15 million people residing in Maryland, Georgia, California, Minnesota, Oregon, Tennessee, and Connecticut were included in the multicenter study (1) . In this study, we calculated the rates of invasive erythromycin-nonsusceptible S. pneumoniae disease, mefE-associated disease, and disease due to mefE-carrying clones in the Baltimore metropolitan area in 1995, 1999, and 2001. These years were chosen to validate the earlier multicenter study in the Baltimore metropolitan area (1995 and 1999) and include 1 year after licensure of PCV7 (2001). PCV7 includes serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. We also assessed whether the mefE-carrying strains were equally distributed in all populations, in all locations, and during both respiratory and nonrespiratory seasons from 1995 to 2001. Cases of invasive pneumococcal disease with an erythromycin MIC >0.5 µg/mL isolated from January 1,1995, to December 31, 2001, were included. Strains with an erythromycin MIC >0.5 µg/mL and penicillin MIC >0.12 µg/mL were defined as erythromycinnonsusceptible and penicillin-nonsusceptible S. pneumoniae, respectively (6) . Pneumococcal serotypes were determined at the Centers for Disease Control and Prevention by the latex agglutination test and confirmed with Quellung reaction. The presence of mef and/or ermB was determined by using a duplex polymerase chain reaction (PCR) (7), and mefA was differentiated from mefE by PCR-restriction fragment length polymorphisms (8) . Pulsed-field gel electrophoresis (PFGE) was performed on all strains (9) . Dendrograms were created in Bionumerics (Applied Maths, Sint-Martens-Latem, Belgium) with a position tolerance of 1.5%. Strains were compared to the first 25 international clones (http://www.sph.emory. edu/PMEN/) (7). Multi-locus sequence typing was performed on 87 (24.5%) of the 349 strains (10, 11) , and included the spectrum of PFGE patterns. Based on PFGE patterns with >80% relatedness by dendrogram, and/or 5 identical alleles, strains were classified into sequence type (ST)-complexes. The following 4 ST-complexes were classified as the clones in this analysis: ST9-complex (related to England 14 -9 clone), ST81-complex (related to Spain 23F -1 clone), ST156-complex (related to Spain 9V -3 clone), and ST236-complex (related to the Taiwan 19F -14 clone).
Rates were calculated by using population estimates from US Census Bureau data for the Baltimore metropolitan area for 1995, 1999, and 2001. Chi-square and Fisher exact tests were used to compare the proportion of the population with disease in 1995, 1999, and 2001 (SAS 8.2, SAS Institute, Cary, NC, USA). Cochran-Armitage trend test was used to compare the proportion of erythromycinnonsusceptible S. pneumoniae strains carrying the mefE gene from 1995 to 2001. Age groups were defined as children <5 years of age and persons >5 years of age; races were defined as persons of white and black race (1); respiratory and nonrespiratory seasons were defined as November-April and May-October, respectively (12) . The incidence of invasive pneumococcal disease significantly increased from 1995 to 1999 before dramatically decreasing from 1999 to 2001. From 1995 to 1999, the overall rates of erythromycin-nonsusceptible S. pneumoniae and mefE-associated disease increased, and then stabilized from 1999 to 2001 (Table) . While the overall rates of erythromycin-nonsusceptible S. pneumoniae were stable, the proportion of pneumococcal strains with reduced susceptibility to erythromycin increased from 5.1% (26/510) in 1995 to 13 Among children <5 years old, the incidence of erythromycin-nonsusceptible S. pneumoniae increased from 1995 to 1999 before declining by 53.6% (p = 0.03) between 1999 and 2001. Likewise, the incidence of mefE-associated disease rose in the 1990s before decreasing by 51.5% from 1999 to 2001 (p = 0.07). The rates of disease due to strains related to the England 14 -9 clone mirrored the agespecific trends from 1995 to 2001 (p<0.05; Table) . In contrast, in persons >5 years of age, the rate of erythromycin-nonsusceptible S. pneumoniae disease remained stable after increasing in the 1990s. From 1999 to 2001, the rate of mefE-associated resistance increased by 54.6% (p = 0.04; Table) . Strains related to the England 14 -9 clone partially accounted for this increase.
Conclusions
The incidence of invasive disease in the Baltimore metropolitan area increased in the 1990s before declining from 1999 to 2001 (13) . Likewise, the rate of invasive erythromycin-nonsusceptible S. pneumoniae disease increased in the 1990s (1) . From 1999 to 2001, the overall incidence of erythromycin-nonsusceptible S. pneumoniae disease and mefE-associated disease stabilized. The proportion of erythromycin-nonsusceptible S. pneumoniae strains carrying the mefE gene dramatically increased from 1995 to 2001. The increase in the proportion of erythromycin-nonsusceptible S. pneumoniae strains carrying the mefE gene over time was detected in patients residing in all 3 geographic locations, from both races, from both age groups, and during both the respiratory and nonrespiratory seasons.
Both the incidence of invasive erythromycin-nonsusceptible S. pneumoniae disease and mefE-associated disease declined by >50% from 1999 to 2001 in children <5 years of age. This decrease was partially due to serotype 14 strains related to the England 14 -9 clone. Strains related to this clone may also account for the substantial decrease in macrolide-resistant serotype 14 infections noted in Atlanta (4) . In contrast to the Atlanta study, the rates of mefE-associated disease increased among persons >5 years. The differences in rates detected in Baltimore compared to Atlanta may reflect regional variation and the inclusion of 2002 in the Atlanta analysis (4) . In this study, the decrease in the incidence of erythromycin-nonsusceptible S. pneumoniae in children may have been due to variation in antimicrobial drug use or to introduction of PCV7.
In summary, after increasing in the 1990s, the rates of invasive erythromycin-nonsusceptible S. pneumoniae disease stabilized overall and decreased in children from 1999 to 2001. This remarkable decline was most likely due to PCV7, although differential antimicrobial drugs may have been a contributor. Unfortunately, the lack of decline in the rate of invasive erythromycin-nonsusceptible S. pneumoniae infections among persons >5 years of age, coupled with the marked increase in dual resistance and the increase in the proportion with erythromycin MICs >16 µg/mL from 1995 to 2001 (14) , is cause for concern. Public health initiatives that focus on judicious use of antimicrobial drugs and the PCV7 vaccine (13) may be beneficial in slowing these trends (15) .
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